While PSA as a blood oncomarker has been used in clinical practice since the late 1980 ́s and early 1990 ́s, the search for another more specific oncomarker that could better predict the presence of (optimally significant) prostate cancer continued. The gene discussed is KLK3; the disease is prostate carcinoma.